Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nabla Bio
Nabla Bio

Nabla Bio

Seed

AI-driven design of therapeutic antibodies for complex diseases.

HQ
Boston, MA, US
Founded
2020
Accelerator
Y Combinator logoY CombinatorS20
Overview
Compare
Fundraising
Employees

Nabla Bio, founded by AI and protein design experts from Harvard University, aims to revolutionize the pharmaceutical and biotech industries by enabling the development of more effective antibody therapies for intractable diseases. The company leverages artificial intelligence and massively parallel experimentation to design antibodies that precisely target disease sites while minimizing risks related to manufacturability and toxicity. Nabla Bio focuses on expanding the universe of druggable targets, using integrated AI and experimental technologies to achieve atomic precision in drug design.

Notable affiliated individuals include its founders, who are recognized experts in AI and protein design from Harvard University. Nabla Bio is a well-funded, revenue-generating company, indicating strong investor confidence and market traction. The company has made significant strides in the field of therapeutic antibody design, contributing to advancements in drug development for complex diseases. Its innovative approach has positioned Nabla Bio as a key player in the biotech industry, with a substantial impact on the future of precision medicine.

Nabla Bio - Similar Companies

Macromoltek logo

Macromoltek

macromoltek.com

BigHat Biosciences logo

BigHat Biosciences

bighatbio.com

Diffuse Bio logo

Diffuse Bio

diffuse.bio

Profluent Bio logo

Profluent Bio

profluent.bio

AI Proteins logo

AI Proteins

aiproteinstx.com

Proteinea logo

Proteinea

proteinea.com

20n logo

20n

Medium Biosciences logo

Medium Biosciences

medium.bio

Abalone Bio logo

Abalone Bio

abalonebio.com

Global Bio logo

Global Bio

Parallel Bio logo

Parallel Bio

parallel.bio

1910 Genetics logo

1910 Genetics

1910genetics.com

BioLoomics logo

BioLoomics

bioloomics.com

TenSixty Biosciences logo

TenSixty Biosciences

tensixty.bio

Regenerative Bio logo

Regenerative Bio

regen-bio.us

Nabla Bio - Quick Facts

Who are Nabla Bio's competitors?

Companies similar to Nabla Bio include Macromoltek, BigHat Biosciences, Diffuse Bio and Profluent Bio.

When was Nabla Bio founded?

Nabla Bio was founded in 2020.

Where is Nabla Bio's headquarters located?

Nabla Bio's headquarters is located in Boston, MA, US.

When was Nabla Bio's last funding round?

Nabla Bio's most recent funding round was for $11M (USD) in December 2021.

How much has Nabla Bio raised to-date?

As of Dec 6, 2021, Nabla Bio has raised a total of $11.3M (USD).

How many employees does Nabla Bio have?

Nabla Bio has 9 employees as of Feb 4, 2024.

Nabla Bio - Classification

Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antibody Design
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software